+

WO2005110990A1 - Heterocycles benzocondenses substitues par hydroxy utilises comme beta-agonistes pour le traitement de maladies respiratoires - Google Patents

Heterocycles benzocondenses substitues par hydroxy utilises comme beta-agonistes pour le traitement de maladies respiratoires Download PDF

Info

Publication number
WO2005110990A1
WO2005110990A1 PCT/EP2005/005027 EP2005005027W WO2005110990A1 WO 2005110990 A1 WO2005110990 A1 WO 2005110990A1 EP 2005005027 W EP2005005027 W EP 2005005027W WO 2005110990 A1 WO2005110990 A1 WO 2005110990A1
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
ethyl
optionally
hydrogen
cooh
Prior art date
Application number
PCT/EP2005/005027
Other languages
German (de)
English (en)
Inventor
Ingo Konetzki
Thierry Bouyssou
Philipp Lustenberger
Marco Santagostino
Andreas Schnapp
Christoph Hoenke
Original Assignee
Boehringer Ingelheim International Gmbh
Boehringer Ingelheim Pharma Gmbh & Co. Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International Gmbh, Boehringer Ingelheim Pharma Gmbh & Co. Kg filed Critical Boehringer Ingelheim International Gmbh
Priority to JP2007512067A priority Critical patent/JP2007537187A/ja
Priority to EP05740683A priority patent/EP1789394A1/fr
Priority to CA002565243A priority patent/CA2565243A1/fr
Publication of WO2005110990A1 publication Critical patent/WO2005110990A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring

Definitions

  • the present invention relates to compounds of general formula 1
  • radicals n, A, B, R 1 , R 2 and R 3 can have the meanings given in the claims and in the description, processes for their preparation and their use as medicaments, in particular as medicaments for the treatment of respiratory diseases.
  • Betamimetics ( ⁇ -adrenergic substances) are known from the prior art.
  • drugs For drug therapy of diseases, it is often desirable to provide drugs with a longer duration of action. This can generally ensure that the concentration of the active ingredient in the organism required to achieve the therapeutic effect is given over a longer period of time without having to repeat the drug too often.
  • the application of an active ingredient at longer intervals also contributes greatly to the well-being of the patient. It is particularly desirable to provide a drug that can be used therapeutically by applying it once per day (single dose). Use once a day has the advantage that the patient can get used to taking the medication regularly at certain times of the day relatively quickly.
  • betamimetics which, on the one hand, have a therapeutic benefit in the treatment of respiratory diseases and, moreover, are characterized by a longer duration of action and thus can be used for the production of drugs with longer efficacy. It is a particular object of the present invention to provide betamimetics which, owing to their long effectiveness, can be used to produce a medicament which can be applied once a day for the therapy of respiratory diseases. In addition to the above-mentioned objects, it is also an object of the present invention to provide those betamimetics which are not only extremely potent, but are also characterized by a high degree of selectivity towards the ⁇ 2 -adrenoceptor. Detailed description of the invention
  • R 1 and R 2 are identical or different, hydrogen, -CC 4 alkyl, halogen, OH or -O- -C alkyl;
  • R 3 is hydrogen, -CC 4 -alkyl, OH, halogen, -O-C ⁇ -C 4 -alkyl, -COOH, -COO-C, -C 4 -alkyl, -OC, -C 4 -alkylene-COOH or -OC ! -C 4 alkylene-CO-O -CC-C 4 alkyl;
  • R 4 and R 5 are the same or different, hydrogen, -CC 4 alkyl, OH, halogen, -OdC 4 alkyl, -COOH or -COO-C ⁇ alkyl;
  • R ° is hydrogen or -CC 4 alkyl
  • R 7 and R 8 are the same or different, hydrogen or -CC 4 alkyl
  • R 9 and R 10 are the same or different, -CC 4 alkyl, optionally in the form of the individual enantiomers, mixtures of the individual enantiomers or racemates, optionally in the form of their acid addition salts with pharmacologically acceptable acids and optionally in the form of the solvates and / or hydrates.
  • n 1 or 2, preferably 1;
  • R 1 and R 2 are the same or different, hydrogen, methyl, ethyl, propyl, fluorine, chlorine, bromine, OH, methoxy or ethoxy;
  • R 3 hydrogen, methyl, ethyl, propyl, fluorine, chlorine, bromine, OH, methoxy, ethoxy, -COOH, -COOMethy
  • n is 1 or 2, preferably 1;
  • R 1 and R 2 are the same or different, hydrogen, methyl, ethyl, fluorine, chlorine, OH, methoxy or ethoxy;
  • R 7 and R 8 are the same or different, hydrogen, methyl or ethyl, preferably hydrogen or methyl
  • R 9 and R 10 are the same or different, methyl or ethyl, preferably methyl, optionally in the form of the individual enantiomers, mixtures of the individual enantiomers or Racemates, optionally in the form of their acid addition salts with pharmacologically acceptable acids and optionally in the form of the solvates and / or hydrates.
  • n is 1 or 2, preferably 1;
  • R 1 and R 2 are the same or different, hydrogen, methyl, ethyl, fluorine, chlorine, OH, methoxy or ethoxy;
  • R 3 is hydrogen, methyl, ethyl, fluorine, chlorine, OH, methoxy, ethoxy, -COOH, -COOMethyl, -COOEthyl, -O-CH 2 -COOH, -O-CH 2 -COO-methyl, -
  • n 1 or 2, preferably 1;
  • R 1 and R 2 are the same or different, hydrogen, methyl, ethyl, fluorine, chlorine, OH, methoxy or ethoxy;
  • R 3 is hydrogen, methyl, ethyl, fluorine, chlorine, OH, methoxy, ethoxy, -COOH, -COOMethyl, -COOEthyl, -O-CH 2 -COOH, -O-CH 2 -COO-methyl, -O-CH 2 -COO-ethyl, -O-CH 2 -CH 2 -COOH, -O-CH 2 -CH 2 -COO-methyl or -O-CH 2 -CH 2 -COO-ethyl;
  • R 9 and R 10 are identical or different, preferably identical, methyl or ethyl, preferably methyl, optionally in the form of the individual enantiomers, mixtures of the individual enantiomers or racemates, optionally in the form of their acid addition salts with pharmacologically acceptable acids and optionally in the form of the solvates and / or hydrates.
  • R 1 and R 2 are the same or different, hydrogen, methyl, ethyl, fluorine, chlorine, OH, methoxy or ethoxy;
  • R 3 is hydrogen, and in which the radicals n, A and B can have the meanings given above, optionally in the form of the individual enantiomers, mixtures of the individual enantiomers or racemates, optionally in the form of their acid addition salts with pharmacologically acceptable acids and optionally in the form of the solvates and / or hydrates.
  • R 1 and R 2 are the same or different, hydrogen, methyl, fluorine, chlorine or methoxy;
  • R 3 is hydrogen, methyl, fluorine, chlorine or methoxy, and in which the radicals n, A and B can have the meanings given above, optionally in the form of the individual enantiomers, mixtures of the individual
  • Enantiomers or racemates optionally in the form of their acid addition salts with pharmacologically acceptable acids and optionally in the form of the solvates and / or hydrates.
  • R 3 methyl, ethyl, fluorine, chlorine, OH, methoxy, ethoxy, -COOH, -COOMethyl, -COOEthyl, -O-CH 2 -COOH, -O-CH 2 -COOMethyl, -O-CH 2 -COOEthyl, - O-CH 2 -CH 2 -COOH, -O-CH 2 -CH 2 -COOMethyl or -O-CH 2 -CH 2 -COOEthyl; means and in which the radicals n, R 1 , R 2 , A, B may have the meanings given above, optionally in the form of the individual enantiomers, mixtures of the individual enantiomers or racemates, optionally in the form of their acid addition salts with pharmacologically acceptable acids and optionally in the form the solvates and / or hydrates.
  • R 3 denotes methyl, ethyl, OH, methoxy, ethoxy, -O-CH 2 -COOH, -O-CH 2 -COOMethyl or -O-CH 2 -COOEthyl, preferably OH, methoxy or ethoxy, and in which the radicals n, R 1 , R 2 , A, B can have the meanings given above, optionally in the form of the individual enantiomers, mixtures of the individual enantiomers or racemates, optionally in the form of their acid addition salts with pharmacologically acceptable acids and optionally in the form of the solvates and / or hydrates.
  • a preferred aspect of the present invention relates to compounds of the formula Ia in which n, R 1 , R 2 and R 3 can have the meanings mentioned above, optionally in the form of the individual enantiomers, mixtures of the individual enantiomers or racemates, optionally in the form of their acid addition salts with pharmacologically harmless acids and optionally in the form of solvates and / or hydrates.
  • a preferred aspect of the present invention relates to compounds of the formula Ib in which n, R, R and R can have the meanings given above, optionally in the form of the individual enantiomers, mixtures of the individual enantiomers or racemates, optionally in the form of their acid addition salts with pharmacologically acceptable acids and optionally in the form of the solvates and / or hydrates.
  • a preferred aspect of the present invention relates to compounds of the formula lc in which n, R 1 , R 2 and R 3 can have the meanings mentioned above, optionally in the form of the individual enantiomers, mixtures of the individual enantiomers or racemates, optionally in the form of their acid addition salts with pharmacologically harmless acids and optionally in the form of solvates and / or hydrates.
  • a preferred aspect of the present invention relates to compounds of the formula Id in which n, R 1 , R 2 and R 3 can have the meanings mentioned above, optionally in the form of the individual enantiomers, mixtures of the individual enantiomers or racemates, optionally in the form of their acid addition salts with pharmacologically harmless acids and optionally in the form of solvates and / or hydrates.
  • a preferred aspect of the present invention relates to compounds of the formula le 19 "in which n, R, R and R can have the meanings mentioned above, optionally in the form of the individual enantiomers, mixtures of the individual enantiomers or racemates, optionally in the form of their acid addition salts with pharmacologically harmless acids and optionally in the form of solvates and / or hydrates.
  • a preferred aspect of the present invention relates to compounds of the formula Ig in which n, R 1 , R 2 and R 3 can have the meanings given above, optionally in the form of the individual enantiomers, mixtures of the individual enantiomers or racemates, optionally in the form of their acid addition salts with pharmacologically harmless acids and optionally in the form of solvates and / or hydrates.
  • a preferred aspect of the present invention relates to compounds of the formula lh in which n, R 1 , R 2 and R 3 can have the meanings mentioned above, optionally in the form of the individual enantiomers, mixtures of the individual enantiomers or racemates, optionally in the form of their acid addition salts with pharmacologically harmless acids and optionally in the form of solvates and / or hydrates.
  • a preferred aspect of the present invention relates to compounds of the formula li wherein n, R 1 , R 2 , R 3 , R 4 and R 5 may have the meanings given above, optionally in the form of the individual enantiomers, mixtures of the individual enantiomers or racemates, if appropriate in the form of their acid addition salts with pharmacologically acceptable acids and optionally in the form of the solvates and / or hydrates.
  • Preferred compounds of the formula Ii in which R 4 is hydrogen and R 5 can have one of the meanings mentioned above, optionally in the form of the individual enantiomers, mixtures of the individual enantiomers or racemates, optionally in the form of their acid addition salts with pharmacologically acceptable acids and, if appropriate in the form of solvates and / or hydrates.
  • a preferred aspect of the present invention relates to compounds of the formula Ij in which n, R 1 , R 2 and R 3 can have the meanings given above, optionally in the form of the individual enantiomers, mixtures of the individual enantiomers or racemates, optionally in the form of their acid addition salts with pharmacologically harmless acids and optionally in the form of solvates and / or hydrates.
  • the hydroxyl function can be linked at 3 positions on the phenyl ring. According to the invention, preference is given to those regioisomers of general formula 1 in which the hydroxyl function is either according to general formula regio-1
  • regio-2 is linked, where the radicals A, B, R 1 , R 2 and R 3 may have the meanings given above, optionally in the form of the individual enantiomers, mixtures of the individual enantiomers or racemates, optionally in the form of their acid addition salts with pharmacologically acceptable Acids and optionally in the form of the solvates and / or hydrates.
  • Particularly preferred compounds of the present inventions are 17 'X
  • Enantiomers mixtures of the individual enantiomers or racemates, optionally in the form of their acid addition salts with pharmacologically acceptable acids and optionally in the form of the solvates and / or hydrates.
  • n, R 1 , R 2 and R 3 can have the meanings given above, optionally in the form of the individual enantiomers, mixtures of the individual enantiomers or racemates, optionally in the form of their acid addition salts with pharmacologically acceptable acids and optionally in the form of Solvates and / or hydrates.
  • n, R 1 , R 2 and R 3 can have the meanings given above, optionally in the form of the individual enantiomers, mixtures of the individual enantiomers or racemates, optionally in the form of their acid addition salts with pharmacologically acceptable acids and optionally in the form of solvates and / or hydrates.
  • n, R 1 , R 2 and R 3 can have the meanings given above, optionally in the form of the individual enantiomers, mixtures of the individual enantiomers or racemates, optionally in the form of their acid addition salts with pharmacologically acceptable acids and optionally in the form of solvates and or hydrates. Accordingly, compounds of the formula Id are of particular importance in which the hydroxyl function corresponds to the general formula re ⁇ io-2d
  • n, R 1 , R 2 and R 3 can have the meanings given above, optionally in the form of the individual enantiomers, mixtures of the individual enantiomers or racemates, optionally in the form of their acid addition salts with pharmacologically acceptable acids and optionally in the form of solvates and / or hydrates.
  • n, R 1 , R 2 and R 3 can have the meanings given above, optionally in the form of the individual enantiomers, mixtures of the individual enantiomers or racemates, optionally in the form of their acid addition salts with pharmacologically acceptable acids and, if appropriate in the form of solvates and / or hydrates.
  • compounds of the formula Ig are particularly important in which the hydroxyl function corresponds to the general formula re ⁇ io-2z re ⁇ io-22nd is linked and in which n, R 1 , R 2 and R 3 can have the meanings given above, optionally in the form of the individual enantiomers, mixtures of the individual enantiomers or racemates, optionally in the form of their acid addition salts with pharmacologically acceptable acids and optionally in the form of Solvates and / or hydrates.
  • n, R, R and R can have the meanings given above, optionally in the form of the individual enantiomers, mixtures of the individual enantiomers or racemates, optionally in the form of their acid addition salts with pharmacologically acceptable acids and optionally in the form of Solvates and / or hydrates.
  • compounds of the formula Ii in which the hydroxyl function corresponds to the general are of particular importance re ⁇ io-2 ⁇ is linked and in which n, R 1 , R 2 , R 3 , R 4 and R 5 may have the meanings given above, optionally in the form of the individual enantiomers, mixtures of the individual enantiomers or racemates, optionally in the form of their Acid addition salts with pharmacologically acceptable acids and optionally in the form of the solvates and / or hydrates.
  • n, R 1 , R 2 and R 3 can have the meanings given above, optionally in the form of the individual enantiomers, mixtures of the individual enantiomers or racemates, optionally in the form of their acid addition salts with pharmacologically acceptable acids and optionally in the form of the solvates and / or hydrates.
  • the radicals R 1 and R 2 if they are not hydrogen, can each be arranged ortho or meta with respect to the linkage to the benzylic “-CH 2 ” group. If none of the radicals R 1 and R 2 is hydrogen, the use according to the invention of those compounds is 1 7 1
  • compounds of general formula 1 which are selected from the group consisting of - 8-hydroxy-5- ⁇ 1-hydroxy-2- [2- (4-methoxyphenyl) -1,1-dimethylethylamino ] - ethyl ⁇ -IH-quinolin-2-one; - 5- ⁇ 2- [2- (2,4-difluorophenyl) -1, l-dimethyl-ethylamino] -l-hydroxyethyl ⁇ -8-hydroxy-3,4-dihydro-1H-quinoline-2 -one; - 8-hydroxy-5- ⁇ 1-hydroxy-2- [2- (4-hydroxyphenyl) -1,1-dimethylethylamino] ethyl ⁇ - 1 H-quinolin-2-one; - 5- ⁇ 2- [2- (4-fluoro-phenyl) -1,1-dimethyl-ethylamino] -1-hydroxy-ethyl ⁇ -8-hydroxy-3,
  • Another aspect of the present invention relates to the above-mentioned new compounds of formula 1 as medicaments.
  • the present invention further relates to the use of the aforementioned compounds of general formula 1 for the manufacture of a medicament for the treatment of respiratory diseases.
  • the present invention preferably relates to the use of the above-mentioned compounds of general formula 1 for the manufacture of a medicament for the treatment of respiratory diseases, which are selected from the group consisting of obstructive lung diseases of different origins, emphysema of different origins, restrictive pulmonary diseases, interstitials
  • Lung diseases cystic fibrosis, bronchitis of various origins, bronchiectasis, ARDS (adult respiratory distress syndrome) and all forms of pulmonary edema.
  • obstructive pulmonary diseases which are selected from the group consisting of COPD (chronic obstructive pulmonary disease), bronchial asthma, pediatric asthma, severe asthma, acute asthma attack and chronic bronchitis, the use of which for the manufacture of a medicament for the treatment bronchial asthma is particularly preferred according to the invention.
  • restrictive lung diseases such as asbestosis or silicosis triggered by noxious agents and restriction due to lung tumors, such as for example Carcinomatous lymphangiosis, bronchoalveolar carcinoma and lymphoma.
  • interstitial lung diseases which are selected from the group consisting of infectious pneumonia, such as, for example, due to an infection with viruses, bacteria, fungi, protozoa, helminths or others Excitation, pneumonitis due to different genesis, such as aspiration and left heart failure, radiation-induced pneumonitis or fibrosis, collagenosis, such as lupus erythematosus, systemic scleroderma or sarcoidosis, granulomatosis, such as Boeck's disease, idiopathic interstitial pneumonia or idiopathic pulmonary fibrosis (fibrosis).
  • infectious pneumonia such as, for example, due to an infection with viruses, bacteria, fungi, protozoa, helminths or others Excitation
  • pneumonitis due to different genesis, such as aspiration and left heart failure, radiation-induced pneumonitis or fibrosis, collagenosis, such as lupus erythematosus, systemic
  • compounds of general formula 1 for the manufacture of a medicament for the treatment of bronchitis, such as, for example, bronchitis due to bacterial or viral infection, allergic bronchitis and toxic bronchitis.
  • compounds of general formula 1 for the manufacture of a medicament for the treatment of ARDS (adult respiratory distress syndrome). It is also preferred to use compounds of general formula 1 for the manufacture of a medicament for the treatment of pulmonary edema, for example toxic pulmonary edema after aspiration or inhalation of toxic substances and foreign substances.
  • the present invention particularly preferably relates to the use of the compounds of the formula 1 for the preparation of a medicament for the treatment of asthma or COPD.
  • the present invention further relates to a method for the treatment of the abovementioned diseases, characterized in that one or more of the abovementioned compounds of the general formula 1 are applied in therapeutically effective amounts.
  • the present invention preferably relates to methods for the treatment of asthma or COPD, characterized in that one or more of the abovementioned compounds of the general formula 1 are administered once a day in therapeutically effective amounts.
  • Another aspect of the present invention relates to the aforementioned new compounds of formula 1 in the form of the individual optical isomers, mixtures of the individual enantiomers or racemates.
  • Compounds of the formula 1 in the form of the enantiomerically pure compounds are particularly preferred, the R-enantiomers of the compounds of the formula 1 being of outstanding importance according to the invention.
  • the R enantiomers of the compounds of formula 1 can be represented by the general formula
  • Another aspect of the present invention relates to the compounds of formula 1 mentioned above in the form of their acid addition salts with pharmacologically acceptable acids and, if appropriate, in the form of the solvates and / or hydrates.
  • salts are selected from the group consisting of hydrochloride, hydrobromide, hydroiodide, hydrosulfate, hydrophosphate, hydromethanesulfonate, hydronitrate, hydromaleate, hydroacetate, hydrobenzoate, hydrocitrate, hydrofumarate, hydratate, and hydrotoxate, hydrooxarate, hydrooxarate, hydrooxarate, hydrooxarate, hydrooxate, hydrooxarate, hydrooxarate, hydrooxate, p-toluenesulfonate, preferably hydrochloride, hydrobromide, hydrosulfate, hydrophosphate, hydrofumarate and hydromethanesulfonate.
  • the salts of hydrochloric acid, maleic acid and fumaric acid and acetic acid are particularly preferred according to the invention.
  • the alkyl groups are branched and unbranched alkyl groups having 1 to 4 carbon atoms. Examples include: methyl, ethyl, propyl or butyl. Abbreviations Me, Et, Prop or Bu may also be used to denote the groups methyl, ethyl, propyl or butyl. Unless otherwise described, the definitions propyl and butyl encompass all conceivable isomeric forms of the respective radicals. For example, propyl includes n-propyl and iso-propyl, butyl includes iso-butyl, sec. Butyl and tert-butyl, etc.
  • alkylene groups are branched and unbranched double-bonded alkyl bridges with 1 to 4 carbon atoms. Examples include: methylene, ethylene, n-propylene or n-butylene.
  • alkyloxy groups designates carbon atoms that are linked via an oxygen atom. Examples include: methylox, ethyloxy, propyloxy or butyloxy.
  • the abbreviations MeO-, EtO-, PropO- or BuO- are also used to denote the groups methyloxy, ethyloxy, propyloxy or butyloxy. Unless otherwise described, the definitions propyloxy and butyloxy encompass all conceivable isomeric forms of the respective radicals.
  • propyloxy includes n-propyloxy and iso-propyloxy
  • butyloxy includes iso-butyloxy, sec. Butyloxy and tert-butyloxy, etc.
  • alkoxy may also be used instead of the term alkyloxy.
  • methoxy, ethoxy, propoxy or butoxy are also used to designate the groups methyloxy, ethyloxy, propyloxy or butyloxy.
  • Halogen in the context of the present invention is fluorine, chlorine, bromine or iodine. Unless stated otherwise, fluorine, chlorine and bromine are preferred halogens.
  • the compounds according to the invention can be prepared analogously to procedures already known in the prior art. Suitable manufacturing processes are known, for example, from US 4460581, to which reference is made here in full.
  • Reaction mixture is heated to 50 ° C for 2 hours, then poured onto ice and concentrated with. Acidified hydrochloric acid. A red-brown solid is isolated, which is repeatedly recrystallized in ethanol with the addition of activated carbon. Yield: 67.5 g (50.6%); Melting range: 163-166 ° C.
  • Example 7 7-Hydroxy-5 - (1-hydroxy-2-r2- (4-methoxy-phenyl) -1.1-dimethyl-ethylamino] -ethyl) -3.4-dihydro-1H-quinolin-2-one
  • Example 8 5- ⁇ 2-r2- (4-ethoxyphenyl) -1, l-dimethyl-ethylamino] -l-hydroxyethyl) -7-hydroxy-3,4-dihydro-1 H-quinoline-2 -one
  • Example 13 7- (2- r2- (4-ethoxy-phenyl) -1,1-dimethyl-ethylamino] -1-hydroxy-ethyl) -5-hvdroxy-3H-benzooxazol-2-one
  • Example 15 8- (2-r2- (4-fluoro-phenyl) -1,1-dimethylethylamino] -1-hydroxyethyl) -6-hydroxy-2,2-dimethyl-4H-benzo 1,4 ] oxazin-3-one
  • Suitable forms of application for applying the compounds of the formula 1 are, for example, tablets, capsules, suppositories, solutions, powders, etc.
  • the proportion of the pharmaceutically active compound (s) should in each case be in the range from 0.05 to 90% by weight, preferably 0.1 up to 50% by weight of the total composition.
  • Corresponding tablets can be mixed, for example, by mixing the active ingredient (s) with known auxiliaries, for example inert diluents such as calcium carbonate, calcium phosphate or milk sugar, disintegrants such as corn starch or alginic acid, binders such as starch or gelatin, lubricants such as
  • Magnesium stearate or talc, and / or agents for achieving the depot effect, such as carboxymethyl cellulose, cellulose acetate phthalate, or polyvinyl acetate can be obtained.
  • the tablets can also consist of several layers.
  • coated tablets can be produced by coating cores produced analogously to the tablets with agents conventionally used in coated tablet coatings, for example collidone or shellac, gum arabic, talc, titanium dioxide or sugar.
  • the core can also consist of several layers to achieve a deposit effect or to avoid incompatibilities.
  • the same can also Drage sleeve to achieve a depot effect consist of several layers, wherein the auxiliaries mentioned above for the tablets can be used.
  • Juices of the active substances or combinations of active substances according to the invention can additionally contain a sweetener, such as saccharin, cyclamate, glycerol or sugar, and a taste-improving agent, for example flavorings, such as vanillin or orange extract. They can also contain suspending agents or thickening agents, such as sodium carboxymethyl cellulose, wetting agents, for example condensation products of fatty alcohols with ethylene oxide, or protective agents, such as p-hydroxybenzoates.
  • Solutions are commonly used, e.g. with the addition of isotonants, preservatives, such as p-hydroxybenzoates, or stabilizers, such as alkali metal salts of ethylenediaminetetraacetic acid, optionally using emulsifiers and / or dispersants, where, for example, when using water as a diluent, organic solvents can optionally be used as solubilizers or auxiliary solvents , manufactured and filled into injection bottles or ampoules or infusion bottles.
  • isotonants e.g. with the addition of isotonants, preservatives, such as p-hydroxybenzoates, or stabilizers, such as alkali metal salts of ethylenediaminetetraacetic acid, optionally using emulsifiers and / or dispersants, where, for example, when using water as a diluent, organic solvents can optionally be used as solubilizers or auxiliary solvents , manufactured and filled into injection
  • the capsules containing one or more active ingredients or combinations of active ingredients can be produced, for example, by inerting the active ingredients
  • ingredients such as milk sugar or sorbitol mix and encapsulate in gelatin capsules.
  • Suitable suppositories can be mixed, for example, with those provided for them
  • Carriers such as neutral fats or polyethylene glycol or the like
  • auxiliary substances are water, pharmaceutically acceptable organic ones
  • Solvents such as paraffins (e.g. petroleum fractions), oils of vegetable origin (e.g. soybean oils), oils of vegetable origin (e.g.
  • Peanut or sesame oil monofunctional or polyfunctional alcohols (e.g. ethanol or
  • Glycerin carriers such as e.g. natural stone flours (e.g. kaolins, clays,
  • Talc chalk
  • synthetic rock flours e.g. highly disperse silica and silicates
  • sugar e.g. cane, milk and glucose
  • emulsifiers e.g. lignin
  • Sufite liquor methyl cellulose, starch and polyvinyl pyrrolidone
  • lubricants e.g.
  • the tablets can of course also contain additives, such as sodium citrate, calcium carbonate and, in addition to the carriers mentioned Contain dicalcium phosphate along with various additives such as starch, preferably potato starch, gelatin and the like.
  • Lubricants such as magnesium stearate, sodium lauryl sulfate and talc can also be used for tableting.
  • the active ingredients can be mixed with various flavor enhancers or colorants.
  • inhalable dosage forms inhalation powders containing propellant gas or propellant-free inhalation solutions come into consideration.
  • propellant-free inhalation solutions also includes concentrates or sterile, ready-to-use inhalation solutions.
  • Inhalable powders which can be used according to the invention can contain 1 either alone or in a mixture with suitable physiologically acceptable auxiliaries. If the active ingredients 1 are contained in a mixture with physiologically acceptable auxiliaries, the following physiologically acceptable auxiliaries can be used to prepare these inhalable powders according to the invention: monosaccharides (e.g. glucose or arabinose), disaccharides (e.g. lactose, sucrose, maltose), oligo- and polysaccharides ( e.g. dextrans), polyalcohols (e.g. sorbitol, mannitol, xylitol), salts (e.g. sodium chloride, calcium carbonate) or mixtures of these auxiliaries with one another.
  • monosaccharides e.g. glucose or arabinose
  • disaccharides e.g. lactose, sucrose, maltose
  • oligo- and polysaccharides e.g. dextrans
  • Mono- or disaccharides are preferably used, the use of lactose or glucose being preferred, in particular, but not exclusively, in the form of their hydrates.
  • Lactose most preferably lactose monohydrate, is used as an auxiliary as particularly preferred in the sense of the invention.
  • the auxiliaries have a maximum average particle size of up to 250 ⁇ m, preferably between 10 and 150 ⁇ m, particularly preferably between 15 and 80 ⁇ m. If appropriate, it may seem sensible to add finer excipient fractions with an average particle size of 1 to 9 ⁇ m to the excipients mentioned above. The latter finer excipients are also selected from the group mentioned above Excipients.
  • micronized active ingredient 1 preferably with an average particle size of 0.5 to 10 ⁇ m, particularly preferably from 1 to 5 ⁇ m, is admixed with the excipient mixture.
  • Processes for producing the inhalable powders according to the invention by grinding and micronizing and by finally mixing the constituents are known from the prior art.
  • the inhalable powders according to the invention can be applied using inhalers known from the prior art.
  • Inhalation aerosols containing propellant gas according to the invention can be dissolved in the propellant gas or contain in dispersed form.
  • the propellant gases which can be used to produce the inhalation aerosols are known from the prior art.
  • Suitable propellants are selected from the group consisting of hydrocarbons such as n-propane, n-butane or isobutane and halogenated hydrocarbons such as fluorinated derivatives of methane, ethane, propane, butane, cyclopropane or cyclobutane.
  • the above-mentioned propellant gases can be used alone or in mixtures thereof.
  • Particularly preferred propellants are halogenated alkane derivatives selected from TG134a and TG227 and mixtures thereof.
  • the inhalation aerosols containing propellant gas may also contain further constituents such as cosolvents, stabilizers, surfactants, antioxidants, lubricants and agents for adjusting the pH. All of these components are known in the art.
  • the active compounds 1 according to the invention can also be applied in the form of propellant-free inhalation solutions and inhalation suspensions.
  • Suitable solvents for this purpose are aqueous or alcoholic, preferably ethanolic, solutions.
  • the solvent can only be water or it is a mixture of water and ethanol.
  • the relative proportion of ethanol to water is not limited, but the maximum limit is preferably up to 70 percent by volume, in particular up to 60 percent by volume and particularly preferably up to 30 percent by volume.
  • the remaining volume percentages are filled up with water.
  • the 1_ containing solutions or suspensions are adjusted to a pH of 2 to 7, preferably 2 to 5, using suitable acids. Acids selected from inorganic or organic acids can be used to adjust this pH. Examples of particularly suitable inorganic acids are hydrochloric acid, hydrobromic acid,
  • Nitric acid, sulfuric acid and or phosphoric acid examples of particularly suitable organic acids are: ascorbic acid, citric acid, malic acid, tartaric acid, maleic acid, succinic acid, fumaric acid, acetic acid, formic acid and / or propionic acid and others.
  • Preferred inorganic acids are hydrochloric acid and sulfuric acid. It is also possible to use the acids which already form an acid addition salt with one of the active ingredients. Ascorbic acid, fumaric acid and citric acid are preferred among the organic acids. If appropriate, mixtures of the acids mentioned can also be used, especially in cases of acids which, in addition to their acidifying properties, also have other properties, e.g. as flavors, antioxidants or complexing agents, such as citric acid or
  • hydrochloric acid is particularly preferably used to adjust the pH.
  • EDTA editic acid
  • sodium edetate sodium edetate
  • the content based on sodium edetate is below 100 mg / 100 ml, preferably below 50 mg / 100 ml, particularly preferably below 20 mg / 100 ml.
  • Inhalation solutions in which the sodium edetate content is 0 to 10 mg / 100 ml are generally preferred.
  • Co-solvents and / or other auxiliaries can be added to the propellant-free inhalation solutions.
  • Preferred co-solvents are those which contain hydroxyl groups or other polar groups, for example alcohols - in particular isopropyl alcohol, glycols - in particular propylene glycol, polyethylene glycol, polypropylene glycol, glycol ether, glycerol, polyoxyethylene alcohols and polyoxyethylene fatty acid esters.
  • auxiliaries and additives are understood to mean any pharmacologically acceptable substance which is not an active substance but can be formulated together with the active substance (s) in the pharmacologically suitable solvent in order to improve the qualitative properties of the active substance formulation.
  • These substances preferably have no or no significant or at least no undesirable pharmacological effect in the context of the desired therapy.
  • auxiliaries and additives include, for example, surface-active substances, such as, for example, soy lecithin, oleic acid, sorbitan esters, such as polysorbates, polyvinylpyrrolidone, other stabilizers, complexing agents, antioxidants and / or preservatives which guarantee or extend the useful life of the finished pharmaceutical formulation, flavors, vitamins and / or others known in the art
  • the additives also include pharmacologically acceptable salts such as sodium chloride as isotonic agents.
  • the preferred auxiliaries include antioxidants, such as ascorbic acid, if not already used for adjusting the pH, vitamin A, vitamin E, tocopherols and similar vitamins or pro vitamins occurring in the human organism.
  • Preservatives can be used to protect the formulation from contamination with germs. Suitable preservatives are those known from the prior art, in particular cetylpyridinium chloride, benzalkonium chloride or benzoic acid or benzoates such as sodium benzoate from those known from the prior art
  • the preservatives mentioned above are preferably present in concentrations of up to 50 mg / 100 ml, particularly preferably between 5 and 20 mg / 100 ml.
  • preferred formulations only contain benzalkonium chloride and sodium edetate.
  • sodium edetate is dispensed with.
  • the dosage of the compounds according to the invention is of course strongly dependent on the type of application and the disease to be treated.
  • the compounds of formula 1 When administered by inhalation, the compounds of formula 1 are highly effective even at doses in the ⁇ g range. Even above the ⁇ g range, the compounds of formula 1 can be used expediently. The dosage can then be in the milligram range, for example.
  • Another aspect of the present invention relates to the pharmaceutical formulations mentioned above, characterized by a content of a compound of the formula 1_ as such, particularly preferably the pharmaceutical formulations mentioned above which can be administered by inhalation.
  • the active ingredient is dissolved in water at its own pH or, if appropriate, at pH 5.5 to 6.5, and sodium chloride is added as an isotonic agent.
  • the solution obtained is filtered pyrogen-free and the filtrate is filled into ampoules under aseptic conditions, which are then sterilized and sealed.
  • the ampoules contain 5 mg, 25 mg and 50 mg of active ingredient.
  • the suspension is filled into a conventional aerosol container with a metering valve. 50 ⁇ l of suspension are preferably dispensed per actuation. If desired, the active ingredient can also be dosed in higher doses
  • the solution is prepared in a conventional manner by mixing the individual components.
  • the inhalable powder is prepared in the usual way by mixing of the individual components.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

L'invention concerne des composés générale (1) dans laquelle n, A, B, R1, R2 et R3 ont la signification indiquée dans les revendications et dans la description. L'invention concerne également des procédés pour la production desdits composés ainsi que l'utilisation de ces derniers comme médicaments, notamment comme médicaments servant au traitement de maladies respiratoires.
PCT/EP2005/005027 2004-05-13 2005-05-10 Heterocycles benzocondenses substitues par hydroxy utilises comme beta-agonistes pour le traitement de maladies respiratoires WO2005110990A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2007512067A JP2007537187A (ja) 2004-05-13 2005-05-10 呼吸器疾患の治療においてβアゴニストとして使用するためのヒドロキシ置換ベンゾ縮合ヘテロ環化合物
EP05740683A EP1789394A1 (fr) 2004-05-13 2005-05-10 Heterocycles benzocondenses substitues par hydroxy utilises comme beta-agonistes pour le traitement de maladies respiratoires
CA002565243A CA2565243A1 (fr) 2004-05-13 2005-05-10 Heterocycles benzocondenses substitues par hydroxy utilises comme beta-agonistes pour le traitement de maladies respiratoires

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04425342.5 2004-05-13
EP04425342 2004-05-13

Publications (1)

Publication Number Publication Date
WO2005110990A1 true WO2005110990A1 (fr) 2005-11-24

Family

ID=34932493

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/005027 WO2005110990A1 (fr) 2004-05-13 2005-05-10 Heterocycles benzocondenses substitues par hydroxy utilises comme beta-agonistes pour le traitement de maladies respiratoires

Country Status (4)

Country Link
EP (1) EP1789394A1 (fr)
JP (1) JP2007537187A (fr)
CA (1) CA2565243A1 (fr)
WO (1) WO2005110990A1 (fr)

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008104781A1 (fr) * 2007-02-28 2008-09-04 Cipla Limited Procédé de préparation d'isomères de carmotérol
US7700782B2 (en) 2006-12-20 2010-04-20 Astrazeneca Ab Compounds 569
US7709511B2 (en) 2005-08-09 2010-05-04 Astrazeneca Ab Benzothiazolone derivatives
JP2010516739A (ja) * 2007-01-25 2010-05-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング β模倣薬の製造方法
WO2010076553A1 (fr) 2008-12-30 2010-07-08 Dr. Reddy's Laboratories Ltd Composés de sulfonamide pour le traitement de troubles respiratoires
WO2010150014A1 (fr) 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited Glitazones 5r-5–deutérés pour le traitement de maladies respiratoires
EP2280006A1 (fr) 2005-08-08 2011-02-02 Pulmagen Therapeutics (Synergy) Limited Composition pharmaceutique pour inhalation comprenant un oxazole ou thiazole antagoniste du récepteur m3 muscarinique
EP2281813A1 (fr) 2005-08-08 2011-02-09 Pulmagen Therapeutics (Synergy) Limited Dérivés de bicyclo[2.2.1]hept-7-ylamine et leurs utilisations
WO2011051671A1 (fr) 2009-10-28 2011-05-05 Vantia Limited Dérivés aminopyridine comme inhibiteurs de la kallicréine
WO2011051672A1 (fr) 2009-10-28 2011-05-05 Vantia Limited Dérivés azaindole
WO2011051673A1 (fr) 2009-10-28 2011-05-05 Vantia Limited Dérivés aminothiazole utiles comme inhibiteurs de la klk1
US7951954B2 (en) 2006-03-14 2011-05-31 Astrazeneca Ab Bezothiazol derivatives as Beta2 adrenoreceptor agonists
WO2011098799A2 (fr) 2010-02-10 2011-08-18 Pulmagen Therapeutics (Inflammation) Limited Traitement de maladie respiratoire
WO2011098746A1 (fr) 2010-02-09 2011-08-18 Pulmagen Therapeutics (Inflammation) Limited Sels d'addition acide cristallins de l'énantiomère (5r) de la pioglitazone
WO2011098801A1 (fr) 2010-02-10 2011-08-18 Pulmagen Therapeutics (Inflammation) Limited Traitement de maladies inflammatoires
US8017602B2 (en) 2008-06-18 2011-09-13 Astrazeneca Ab N-(2-(2-(5-hydroxy-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl)ethylamino)ethyl)-3-(phenethoxy)propanamide derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy
US8058294B2 (en) 2007-02-08 2011-11-15 Astrazeneca Ab Pharmaceutical salts of N-[2-(diethylamino)ethyl]-N-(2-{[2-(4-hydroxy-2-oxo-2,3-dihydro-1,3-benzothiazol-7-yl)ethyl]amino}ethyl)-3-[2-(1-napthyl)ethoxy]propanamide
US8076489B2 (en) 2004-11-29 2011-12-13 Novartis Ag 5-hydroxy-benzothiazole derivatives having beta-2-adrenoreceptor agonist activity
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
WO2013035047A1 (fr) 2011-09-06 2013-03-14 Novartis Ag Composé de benzothiazolone
EP1789405B1 (fr) * 2004-05-14 2013-07-17 Boehringer Ingelheim International Gmbh Nouveaux beta-agonistes enantiomeriquement purs, leur procede de production et leur utilisation comme medicament
WO2014033654A1 (fr) 2012-08-30 2014-03-06 Novartis Ag Sels de composé benzothiazolone utilisés en tant qu'agoniste de beta-2-adrenoceptor
WO2014132205A1 (fr) 2013-02-28 2014-09-04 Novartis Ag Préparation contenant un composé de benzothiazolone
US10288602B2 (en) 2013-01-08 2019-05-14 Atrogi Ab Screening method, a kit, a method of treatment and a compound for use in a method of treatement
US11357757B2 (en) 2017-09-13 2022-06-14 Atrogi Ab Heteroaryl substituted beta-hydroxyethylamines for use in treating hyperglycaemia
US11427539B2 (en) 2017-09-13 2022-08-30 Atrogi Ab Beta-hydroxy heterocyclic amines and their use in the treatment of hyperglycaemia
US11648216B2 (en) 2017-09-13 2023-05-16 Atrogi Ab Fluorophenyl beta-hydroxyethylamines and their use in the treatment of hyperglycaemia
US11793774B2 (en) 2017-09-13 2023-10-24 Atrogi Ab Chiral beta-hydroxyethylamines and their use in the treatment of hyperglycemia
WO2023203223A1 (fr) 2022-04-22 2023-10-26 Atrogi Ab Combinaisons d'agonistes du récepteur bêta 2-adrénergique et d'agonistes du récepteur bêta 3-adrénergique et leurs utilisations médicales
WO2024153813A1 (fr) 2023-01-20 2024-07-25 Atrogi Ab Agonistes du récepteur bêta 2-adrénergique pour le traitement ou la prévention de l'atrophie musculaire
WO2024170727A1 (fr) 2023-02-16 2024-08-22 Atrogi Ab Combinaisons d'agonistes du récepteur bêta 2-adrénergique et de metformine destinées à être utilisées dans le traitement de l'obésité et la réduction de la graisse corporelle
WO2024184408A1 (fr) 2023-03-06 2024-09-12 Atrogi Ab Combinaison d'agonistes du récepteur bêta-2-adrénergique et d'agonistes du récepteur glp-1 destinés à être utilisés dans le traitement de l'hyperglycémie

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS51128982A (en) * 1975-04-29 1976-11-10 Higuchi Yoshinari New corbostyril derivatives and pharmaceutical compositions containing thereof
JPS51141880A (en) * 1975-05-28 1976-12-07 Otsuka Pharmaceut Co Ltd Process for preparing carbostyril derivatives
JPS52283A (en) * 1975-06-23 1977-01-05 Otsuka Pharmaceut Co Ltd Process for preparation of carbostyril derivatives
DE2658544A1 (de) * 1976-10-08 1978-04-13 Otsuka Pharma Co Ltd Carbostyrilderivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3134590A1 (de) * 1981-09-01 1983-03-10 Boehringer Ingelheim KG, 6507 Ingelheim Neue benzo-heterocyclen
US4460581A (en) * 1982-10-12 1984-07-17 Boehringer Ingelheim Kg (1-Hydroxy-2-amino-alkyl)-substituted benzoxazinones and benzoxazolinones
US4894219A (en) * 1988-03-29 1990-01-16 University Of Florida Beta-agonist carbostyril derivatives, assay method and pharmacological composition
WO2004016601A1 (fr) * 2002-08-09 2004-02-26 Novartis Ag Derives de benzothiazole ayant une activite d'agoniste du beta-2-adrenorecepteur

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5629301A (en) * 2000-04-27 2001-11-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel, slow-acting betamimetics, a method for their production and their use as medicaments
DE10253282A1 (de) * 2002-11-15 2004-05-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS51128982A (en) * 1975-04-29 1976-11-10 Higuchi Yoshinari New corbostyril derivatives and pharmaceutical compositions containing thereof
JPS51141880A (en) * 1975-05-28 1976-12-07 Otsuka Pharmaceut Co Ltd Process for preparing carbostyril derivatives
JPS52283A (en) * 1975-06-23 1977-01-05 Otsuka Pharmaceut Co Ltd Process for preparation of carbostyril derivatives
DE2658544A1 (de) * 1976-10-08 1978-04-13 Otsuka Pharma Co Ltd Carbostyrilderivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3134590A1 (de) * 1981-09-01 1983-03-10 Boehringer Ingelheim KG, 6507 Ingelheim Neue benzo-heterocyclen
US4460581A (en) * 1982-10-12 1984-07-17 Boehringer Ingelheim Kg (1-Hydroxy-2-amino-alkyl)-substituted benzoxazinones and benzoxazolinones
US4894219A (en) * 1988-03-29 1990-01-16 University Of Florida Beta-agonist carbostyril derivatives, assay method and pharmacological composition
WO2004016601A1 (fr) * 2002-08-09 2004-02-26 Novartis Ag Derives de benzothiazole ayant une activite d'agoniste du beta-2-adrenorecepteur

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; NAKAGAWA, KAZUYUKI ET AL: "5-(1-Hydroxy-2-aminoalkyl)carbostyrils and their pharmaceutical compositions", XP002300110, retrieved from STN Database accession no. 1977:453105 *
DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; NAKAGAWA, KAZUYUKI ET AL: "Carbostyril derivatives", XP002300112, retrieved from STN Database accession no. 1977:405825 *
DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; YOSHIZAKI, SHIRO ET AL: "Carbostyril derivatives", XP002300111, retrieved from STN Database accession no. 1977:453102 *
DEYRUP M D ET AL: "STRUCTURE-AFFINITY PROFILE OF 8-HYDROXYCARBOSTYRIL-BASED AGONISTS THAT DISSOCIATE SLOWLY FROM THE BETA2-ADRENOCEPTOR", NAUNYN-SCHMIEDEBERG'S ARCHIVES OF PHARMACOLOGY, SPRINGER, BERLIN, DE, vol. 359, no. 3, 1999, pages 168 - 177, XP001199515, ISSN: 0028-1298 *
YOSHIZAKI, SHIRO ET AL: "Sympathomimetic amines having a 3,4-dihydrocarbostyril nucleus", CHEMICAL & PHARMACEUTICAL BULLETIN , 26(5), 1611-14 CODEN: CPBTAL; ISSN: 0009-2363, 1978, XP009034840 *
YOSHIZAKI, SHIRO ET AL: "Sympathomimetic amines having a carbostyril nucleus", JOURNAL OF MEDICINAL CHEMISTRY , 19(9), 1138-42 CODEN: JMCMAR; ISSN: 0022-2623, 1976, XP002291187 *

Cited By (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1789405B1 (fr) * 2004-05-14 2013-07-17 Boehringer Ingelheim International Gmbh Nouveaux beta-agonistes enantiomeriquement purs, leur procede de production et leur utilisation comme medicament
US8076489B2 (en) 2004-11-29 2011-12-13 Novartis Ag 5-hydroxy-benzothiazole derivatives having beta-2-adrenoreceptor agonist activity
EP2281813A1 (fr) 2005-08-08 2011-02-09 Pulmagen Therapeutics (Synergy) Limited Dérivés de bicyclo[2.2.1]hept-7-ylamine et leurs utilisations
EP2280006A1 (fr) 2005-08-08 2011-02-02 Pulmagen Therapeutics (Synergy) Limited Composition pharmaceutique pour inhalation comprenant un oxazole ou thiazole antagoniste du récepteur m3 muscarinique
US7709511B2 (en) 2005-08-09 2010-05-04 Astrazeneca Ab Benzothiazolone derivatives
US7951954B2 (en) 2006-03-14 2011-05-31 Astrazeneca Ab Bezothiazol derivatives as Beta2 adrenoreceptor agonists
US7700782B2 (en) 2006-12-20 2010-04-20 Astrazeneca Ab Compounds 569
JP2010516739A (ja) * 2007-01-25 2010-05-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング β模倣薬の製造方法
US8058294B2 (en) 2007-02-08 2011-11-15 Astrazeneca Ab Pharmaceutical salts of N-[2-(diethylamino)ethyl]-N-(2-{[2-(4-hydroxy-2-oxo-2,3-dihydro-1,3-benzothiazol-7-yl)ethyl]amino}ethyl)-3-[2-(1-napthyl)ethoxy]propanamide
US8236959B2 (en) 2007-02-28 2012-08-07 Cipla Limited Process for preparing isomers of carmoterol
WO2008104781A1 (fr) * 2007-02-28 2008-09-04 Cipla Limited Procédé de préparation d'isomères de carmotérol
AU2008220617B2 (en) * 2007-02-28 2012-12-06 Cipla Limited Process for preparing isomers of carmoterol
US8017602B2 (en) 2008-06-18 2011-09-13 Astrazeneca Ab N-(2-(2-(5-hydroxy-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl)ethylamino)ethyl)-3-(phenethoxy)propanamide derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy
US9078885B2 (en) 2008-08-07 2015-07-14 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
US8815837B2 (en) 2008-08-07 2014-08-26 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
US8362064B2 (en) 2008-12-30 2013-01-29 Pulmagen Theraputics (Inflammation) Limited Sulfonamide compounds for the treatment of respiratory disorders
WO2010076553A1 (fr) 2008-12-30 2010-07-08 Dr. Reddy's Laboratories Ltd Composés de sulfonamide pour le traitement de troubles respiratoires
WO2010150014A1 (fr) 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited Glitazones 5r-5–deutérés pour le traitement de maladies respiratoires
WO2011051673A1 (fr) 2009-10-28 2011-05-05 Vantia Limited Dérivés aminothiazole utiles comme inhibiteurs de la klk1
WO2011051672A1 (fr) 2009-10-28 2011-05-05 Vantia Limited Dérivés azaindole
WO2011051671A1 (fr) 2009-10-28 2011-05-05 Vantia Limited Dérivés aminopyridine comme inhibiteurs de la kallicréine
WO2011098746A1 (fr) 2010-02-09 2011-08-18 Pulmagen Therapeutics (Inflammation) Limited Sels d'addition acide cristallins de l'énantiomère (5r) de la pioglitazone
WO2011098801A1 (fr) 2010-02-10 2011-08-18 Pulmagen Therapeutics (Inflammation) Limited Traitement de maladies inflammatoires
WO2011098799A2 (fr) 2010-02-10 2011-08-18 Pulmagen Therapeutics (Inflammation) Limited Traitement de maladie respiratoire
US9913828B2 (en) 2011-09-06 2018-03-13 Novartis Ag Benzothiazolone compound
US8933108B2 (en) 2011-09-06 2015-01-13 Novartis Ag Benzothiazolone compound
WO2013035047A1 (fr) 2011-09-06 2013-03-14 Novartis Ag Composé de benzothiazolone
US10251868B2 (en) 2011-09-06 2019-04-09 Novartis Ag Benzothiazolone compound
WO2014033654A1 (fr) 2012-08-30 2014-03-06 Novartis Ag Sels de composé benzothiazolone utilisés en tant qu'agoniste de beta-2-adrenoceptor
EP3243817A1 (fr) 2012-08-30 2017-11-15 Novartis AG Sel d'un composé de benzothiazolone comme agoniste de beta-2-adrenocepteur
US10288602B2 (en) 2013-01-08 2019-05-14 Atrogi Ab Screening method, a kit, a method of treatment and a compound for use in a method of treatement
WO2014132205A1 (fr) 2013-02-28 2014-09-04 Novartis Ag Préparation contenant un composé de benzothiazolone
US11427539B2 (en) 2017-09-13 2022-08-30 Atrogi Ab Beta-hydroxy heterocyclic amines and their use in the treatment of hyperglycaemia
US11357757B2 (en) 2017-09-13 2022-06-14 Atrogi Ab Heteroaryl substituted beta-hydroxyethylamines for use in treating hyperglycaemia
US11648216B2 (en) 2017-09-13 2023-05-16 Atrogi Ab Fluorophenyl beta-hydroxyethylamines and their use in the treatment of hyperglycaemia
US11793774B2 (en) 2017-09-13 2023-10-24 Atrogi Ab Chiral beta-hydroxyethylamines and their use in the treatment of hyperglycemia
US12036210B2 (en) 2017-09-13 2024-07-16 Atrogi Ab Heteroaryl substituted beta-hydroxyethylamines for use in treating hyperglycaemia
WO2023203223A1 (fr) 2022-04-22 2023-10-26 Atrogi Ab Combinaisons d'agonistes du récepteur bêta 2-adrénergique et d'agonistes du récepteur bêta 3-adrénergique et leurs utilisations médicales
WO2024153813A1 (fr) 2023-01-20 2024-07-25 Atrogi Ab Agonistes du récepteur bêta 2-adrénergique pour le traitement ou la prévention de l'atrophie musculaire
WO2024170727A1 (fr) 2023-02-16 2024-08-22 Atrogi Ab Combinaisons d'agonistes du récepteur bêta 2-adrénergique et de metformine destinées à être utilisées dans le traitement de l'obésité et la réduction de la graisse corporelle
WO2024184408A1 (fr) 2023-03-06 2024-09-12 Atrogi Ab Combinaison d'agonistes du récepteur bêta-2-adrénergique et d'agonistes du récepteur glp-1 destinés à être utilisés dans le traitement de l'hyperglycémie

Also Published As

Publication number Publication date
EP1789394A1 (fr) 2007-05-30
JP2007537187A (ja) 2007-12-20
CA2565243A1 (fr) 2005-11-24

Similar Documents

Publication Publication Date Title
WO2005110990A1 (fr) Heterocycles benzocondenses substitues par hydroxy utilises comme beta-agonistes pour le traitement de maladies respiratoires
EP1562603B3 (fr) Nouveaux medicaments destines au traitement de la bronchopneumopathie chronique obstructive
EP1911749B1 (fr) Nouveaux agoniste béta-2 à action prolongée et leur utilisation en tant que médicament
EP1789405B1 (fr) Nouveaux beta-agonistes enantiomeriquement purs, leur procede de production et leur utilisation comme medicament
EP1794154B1 (fr) Composes heteroaryle en tant que betamimetiques pour traiter des maladies des voies respiratoires
EP1761509B1 (fr) Dérivés de cycloalkyle pour le traitement des maladies respiratoires
DE10253220A1 (de) Neue Dihydroxy-Methyl-Phenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
EP1853596B1 (fr) Nouveaux betamimetiques a effet prolonge pour traiter des affections des voies respiratoires
EP1747208B1 (fr) Nouveaux bronchodilatateurs pour le traitement de maladies respiratoires
DE10246374A1 (de) Neue Betamimetika mit verlängerter Wirkungsdauer, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
EP1765355B1 (fr) Benzoxazines destinees au traitement de maladies des voies respiratoires
EP1720546B1 (fr) Nouveaux beta-2-agonistes a action longue duree et leur utilisation comme medicaments
EP1856070B1 (fr) Nouveaux medicaments pour traiter des maladies des voies respiratoires
WO2005066140A1 (fr) Derives 3-hydroxymethyl-4-hydroxyphenyle pour le traitement de maladies des voies respiratoires
DE10258695A1 (de) Neuer, langwirksamer Beta-agonist, Verfahren zu dessen Herstellung und dessen Verwendung als Arzneimittel

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005740683

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2565243

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007512067

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWP Wipo information: published in national office

Ref document number: 2005740683

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载